Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Barr Will Begin First Self-Sponsored Clinical Trial For An NDA This Fall

Executive Summary

Barr Labs will begin clinical trials on a prostate cancer therapy this fall, the first time it will be conducting its own clinical trials, Barr CEO Bruce Downey said during an Aug. 10 teleconference.

You may also be interested in...



Mylan To File CNS NDAs/ANDAs By Year End Via Synthon Deal

Mylan will file several NDAs and ANDAs for central nervous system treatments over the next two months as part of its collaboration with the Dutch pharmaceutical firm Synthon.

Mylan To File CNS NDAs/ANDAs By Year End Via Synthon Deal

Mylan will file several NDAs and ANDAs for central nervous system treatments over the next two months as part of its collaboration with the Dutch pharmaceutical firm Synthon.

Gabapentin ANDA Comparing Tabs To Caps Is Not Complete, Petition Says

An ANDA for gabapentin tablets that references Warner-Lambert's Neurontin capsules should be treated by the agency as "not substantially complete," an Aug. 12 citizen's petition to FDA argues.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS034663

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel